SIC 2835 · Manufacturing

In Vitro & In Vivo Diagnostic Substances

OpenFilings tracks 8 companies that the SEC classifies under Standard Industrial Classification code 2835; the most recent filing among them is dated Oct 27, 2026. 8 of them report standardized annual figures in XBRL, shown in the revenue column.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. Not investment advice.

Companies in this industry

In Vitro & In Vivo Diagnostic Substances companies (SIC 2835)
#CompanyStateLatest filingRevenue (latest FY)
355IDXX IDEXX LABORATORIES INC /DEMESep 9, 2026$4.3BFY2025
1149LNTH Lantheus Holdings, Inc.MAOct 22, 2026$1.5BFY2025
1799NEOG NEOGEN CORPMIOct 26, 2026$870.4MFY2026
1891CLDX Celldex Therapeutics, Inc.NJOct 7, 2026$1.5MFY2025
2153NTLA Intellia Therapeutics, Inc.MAOct 6, 2026$67.7MFY2025
2477QDEL QuidelOrtho CorpCAOct 19, 2026$2.7BFY2025
2718ACHV ACHIEVE LIFE SCIENCES, INC.WAOct 6, 2026—FY2025
2844MYGN MYRIAD GENETICS INCUTOct 27, 2026$824.5MFY2025

Ranked by position in the SEC company ticker list (roughly by market value) among all companies we track. Revenue is the latest full fiscal year; amounts in a foreign currency are shown with its code.

Latest reports from these companies

Annual, quarterly and current reports and proxy statements filed by the companies above, newest first.

Recent filings, SIC 2835
FiledCompanyFormWhat it isOriginal
Oct 26, 2026NEOG NEOGEN CORP8-K/ADirector or officer change· period Oct 1, 2026Document · Index
Oct 22, 2026LNTH Lantheus Holdings, Inc.8-KOther events· period Oct 21, 2026Document · Index
Oct 20, 2026MYGN MYRIAD GENETICS INC8-KMaterial agreement; Regulation FD disclosure· period Oct 19, 2026Document · Index
Oct 14, 2026LNTH Lantheus Holdings, Inc.8-KShareholder vote results· period Oct 14, 2026Document · Index
Oct 9, 2026MYGN MYRIAD GENETICS INC8-KDirector or officer change· period Oct 6, 2026Document · Index
Oct 7, 2026NEOG NEOGEN CORP10-QQuarterly report· period Aug 31, 2026Document · Index
Oct 7, 2026NEOG NEOGEN CORP8-KShareholder vote results· period Oct 1, 2026Document · Index
Oct 6, 2026NEOG NEOGEN CORP8-KResults of operations· period Oct 6, 2026Document · Index
Oct 2, 2026LNTH Lantheus Holdings, Inc.8-KOther events· period Oct 2, 2026Document · Index
Oct 1, 2026ACHV ACHIEVE LIFE SCIENCES, INC.8-KDirector or officer change· period Oct 1, 2026Document · Index
Sep 23, 2026QDEL QuidelOrtho Corp8-KMaterial agreement· period Sep 23, 2026Document · Index
Sep 22, 2026CLDX Celldex Therapeutics, Inc.8-KOther events· period Sep 22, 2026Document · Index
Sep 21, 2026LNTH Lantheus Holdings, Inc.8-KOther events· period Sep 17, 2026Document · Index
Sep 16, 2026MYGN MYRIAD GENETICS INC8-KDirector or officer change; Regulation FD disclosure· period Sep 15, 2026Document · Index
Sep 8, 2026NTLA Intellia Therapeutics, Inc.8-KRegulation FD disclosure; Other events· period Sep 8, 2026Document · Index
Sep 4, 2026NTLA Intellia Therapeutics, Inc.8-KMaterial agreement; New financial obligation; Regulation FD disclosure· period Sep 4, 2026Document · Index
Aug 21, 2026NEOG NEOGEN CORPDEF 14ADefinitive proxy statement· period Aug 21, 2026Document · Index
Aug 14, 2026ACHV ACHIEVE LIFE SCIENCES, INC.8-KOther events· period Aug 14, 2026Document · Index
Aug 11, 2026ACHV ACHIEVE LIFE SCIENCES, INC.10-QQuarterly report· period Jun 30, 2026Document · Index
Aug 11, 2026ACHV ACHIEVE LIFE SCIENCES, INC.8-KResults of operations· period Aug 11, 2026Document · Index
Aug 7, 2026NEOG NEOGEN CORP8-KDirector or officer change· period Aug 3, 2026Document · Index
Aug 7, 2026QDEL QuidelOrtho Corp10-QQuarterly report· period Jun 28, 2026Document · Index
Aug 6, 2026CLDX Celldex Therapeutics, Inc.8-KResults of operations· period Aug 6, 2026Document · Index
Aug 6, 2026CLDX Celldex Therapeutics, Inc.10-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 2026LNTH Lantheus Holdings, Inc.10-QQuarterly report· period Jun 30, 2026Document · Index

Related industries in Manufacturing

All industries · All companies

Source

  • U.S. Securities and Exchange Commission, EDGAR company submissions (SIC code and description) and XBRL company facts. The SEC does not endorse OpenFilings.